KRMD
KORU Medical Systems, Inc. NASDAQ Listed Apr 5, 1994$4.44
Mkt Cap $206.5M
52w Low $2.62
45.6% of range
52w High $6.61
50d MA $4.32
200d MA $4.54
P/E (TTM)
-71.3x
EV/EBITDA
-121.6x
P/B
11.0x
Debt/Equity
0.2x
ROE
-15.5%
P/FCF
-570.8x
RSI (14)
—
ATR (14)
—
Beta
0.54
50d MA
$4.32
200d MA
$4.54
Avg Volume
191.3K
KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
24 Carpenter Road · Mahwah, NY 10918 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.02 | -0.02 | +0.0% | 4.01 | +12.0% | +10.7% | — | — | — | — | — |
| Mar 12, 2026 | AMC | -0.02 | -0.01 | +50.0% | 4.31 | +0.0% | -0.7% | -0.5% | -0.9% | +0.9% | -0.2% | — |
| Nov 12, 2025 | AMC | -0.03 | -0.02 | +33.3% | 3.78 | +5.8% | +15.1% | +14.3% | +18.8% | +18.3% | +15.1% | — |
| Aug 6, 2025 | AMC | -0.03 | 0.01 | +133.3% | 3.26 | +4.6% | +18.7% | +21.5% | +23.9% | +27.3% | +31.9% | — |
| May 7, 2025 | AMC | -0.02 | -0.03 | -50.0% | 2.72 | +8.5% | +21.0% | +15.8% | +19.5% | +18.0% | +10.7% | — |
| Mar 12, 2025 | AMC | -0.03 | -0.03 | +0.0% | 3.28 | -4.0% | -17.7% | -15.5% | -9.5% | -11.6% | -11.0% | — |
| Nov 13, 2024 | AMC | -0.02 | -0.03 | -21.0% | 3.20 | +6.2% | -3.8% | -0.9% | -1.6% | +3.4% | +14.1% | — |
| Aug 7, 2024 | AMC | -0.01 | -0.02 | -52.6% | 2.13 | +15.5% | +16.4% | +19.2% | +15.5% | +11.3% | +8.5% | — |
| May 1, 2024 | AMC | -0.01 | -0.02 | -47.2% | 2.25 | +0.9% | +5.8% | +3.1% | +2.7% | +0.4% | +0.0% | — |
| Mar 13, 2024 | AMC | -0.02 | -0.02 | -25.0% | 2.12 | +3.8% | +3.3% | +3.8% | -1.9% | -2.8% | +8.5% | — |
| Nov 8, 2023 | AMC | -0.02 | -0.03 | -40.1% | 2.19 | -3.7% | -7.3% | -2.3% | -3.2% | +5.0% | -0.9% | — |
| Aug 9, 2023 | AMC | -0.05 | -0.05 | +0.0% | 2.37 | -4.6% | +4.2% | +5.9% | +8.4% | +7.6% | +8.9% | — |
| May 4, 2023 | AMC | -0.04 | -0.05 | -25.0% | 4.06 | -3.9% | -1.2% | -3.4% | -6.2% | -4.2% | -2.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13 | B. Riley Securities | Maintains | Buy → Buy | — | $4.31 | $4.31 | +0.0% | -0.7% | -0.5% | -0.9% | +0.9% | -0.2% |
| Mar 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.31 | $4.31 | +0.0% | -0.7% | -0.5% | -0.9% | +0.9% | -0.2% |
| Dec 22 | Lake Street | Maintains | Buy → Buy | — | $5.80 | $5.93 | +2.2% | +4.7% | +12.4% | +11.7% | +7.4% | +4.5% |
| Dec 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.77 | $5.79 | +0.3% | -4.5% | -0.3% | +0.5% | +5.2% | +13.0% |
| Aug 7 | Piper Sandler | Maintains | Neutral → Neutral | — | $3.26 | $3.41 | +4.6% | +18.7% | +21.5% | +23.9% | +27.3% | +31.9% |
| May 8 | Piper Sandler | Maintains | Neutral → Neutral | — | $2.72 | $2.95 | +8.5% | +21.0% | +15.8% | +19.5% | +18.0% | +10.7% |
| Feb 14 | Piper Sandler | Downgrade | Overweight → Neutral | — | $4.75 | $4.50 | -5.3% | -8.0% | -12.6% | -15.8% | -18.3% | -21.9% |
| Jan 17 | Craig-Hallum | Maintains | Buy → Buy | — | $4.00 | $4.08 | +2.0% | +2.2% | +3.5% | +2.2% | +2.5% | +3.0% |
| Jan 14 | Lake Street | Maintains | Buy → Buy | — | $3.95 | $4.06 | +2.8% | +3.0% | -0.3% | +1.3% | +3.5% | +4.8% |
| Nov 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.20 | $3.40 | +6.2% | -3.8% | -0.9% | -1.6% | +3.4% | +14.1% |
| Nov 14 | Craig-Hallum | Maintains | Buy → Buy | — | $3.20 | $3.40 | +6.2% | -3.8% | -0.9% | -1.6% | +3.4% | +14.1% |
| Nov 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $3.20 | $3.40 | +6.2% | -3.8% | -0.9% | -1.6% | +3.4% | +14.1% |
| Aug 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.13 | $2.46 | +15.5% | +16.4% | +19.2% | +15.5% | +11.3% | +8.5% |
| Mar 14 | B. Riley Securities | Maintains | Buy → Buy | — | $2.12 | $2.20 | +3.8% | +3.3% | +3.8% | -1.9% | -2.8% | +8.5% |
| Dec 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $2.28 | $2.29 | +0.4% | +3.5% | +4.4% | +0.9% | +1.8% | +5.3% |
| Aug 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.48 | $2.47 | -0.4% | +2.8% | +2.0% | -0.8% | -1.6% | -4.4% |
| Jan 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $3.70 | $3.82 | +3.2% | +3.2% | +6.8% | +10.8% | +8.6% | +8.9% |
| Nov 10 | Piper Sandler | Upgrade | Neutral → Overweight | — | $2.31 | $2.47 | +6.9% | +16.9% | +28.6% | +26.4% | +26.4% | +21.2% |
| Nov 10 | Canaccord Genuity | Upgrade | Hold → Buy | — | $2.31 | $2.47 | +6.9% | +16.9% | +28.6% | +26.4% | +26.4% | +21.2% |
| Jan 26 | Piper Sandler | Downgrade | Overweight → Neutral | — | $5.13 | $4.19 | -18.3% | -15.6% | -17.3% | -19.5% | -21.2% | -21.8% |
| Jan 26 | Canaccord Genuity | Downgrade | Buy → Hold | — | $5.13 | $4.19 | -18.3% | -15.6% | -17.3% | -19.5% | -21.2% | -21.8% |
| Nov 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.16 | $4.18 | +0.5% | -2.4% | -4.3% | -8.2% | -7.9% | -6.2% |
| Jul 16 | Canaccord Genuity | Maintains | Buy → Buy | — | $9.49 | $9.79 | +3.2% | +3.7% | +6.3% | +4.2% | +3.9% | +2.2% |
| Jun 24 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.98 | $9.32 | +3.8% | +3.3% | +3.2% | -4.3% | -1.8% | +0.0% |
No insider trades available.
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
KRMD signed a material agreement with HSBC Ventures USA Inc., signaling potential strategic partnership, funding, or technology collaboration that could accelerate growth and validate the business model.
Apr 3
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
KRMD's CEO departure effective year-end 2026 signals potential leadership transition uncertainty, which investors should monitor for strategic direction changes and management capability concerns.
Mar 16
8-K
Unknown — 8-K Filing
Kermed appears to be restructuring operations while excluding significant non-cash items from profitability metrics, suggesting management expects near-term losses but wants investors focused on operational cash generation potential.
Mar 12
8-K · 5.03
! Medium
KORU Medical Systems, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
KORU Medical Systems changed its fiscal year end, which may affect financial reporting schedules and investor timing for earnings announcements and tax planning.
Feb 11
Data updated apr 25, 2026 5:59pm
· Source: massive.com